Sepracor Insomnia Agent Lunesta Priced At Premuim To Ambien
This article was originally published in The Pink Sheet Daily
Executive Summary
Lunesta, formerly Estorra, has AWP of $3.70 for 1 mg, 2 mg and 3 mg tablets; Sanofi-Aventis’ Ambien has AWP of $2.50 for 5 mg tablet and $3.07 for 10 mg tablet. DTC campaign will highlight Lunesta’s duration of action.
You may also be interested in...
Lunesta’s Expanded Sales Force Will Focus On Maintenance Use
Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.
Lunesta’s Expanded Sales Force Will Focus On Maintenance Use
Sepracor said it does not plan to use negative publicity about side effects with Sanofi-Aventis’ Ambien to gain a competitive edge.
Sepracor Plans April 4 Lunesta Launch
Sepracor will launch the insomnia agent upon same-day publication of the final rule designating Lunesta as a Schedule IV controlled substance. More than 40,000 retail pharmacies already have placed orders for eszopiclone, the company says.